Table 3 A correlation between pathogenic germline mutations and risk of AML in analyzed patients
From: Germline mutations among Polish patients with acute myeloid leukemia
Gene | Mutations | Number of pathogenic germline mutations | OR | 95 % CI | p-value | |||
|---|---|---|---|---|---|---|---|---|
Tested group n = 103 [n/%] | Control group n = 103 [n/%] | |||||||
CEBPA | c.337_344del | 1 | 0.97 % | 0 | 0.00 % | 3.03 | 0.122–75.235 | p = 0.499 |
590_591insACCCGC | 4 | 3,88 % | 1 | 0.97 % | 4.12 | 0.453–37.520 | p = 0.209 | |
ETV6 | c.1075 C > T | 1 | 0.97 % | 0 | 0.00 % | 3.03 | 0.122–75.235 | p = 0.499 |
IDH2 | c.419G > A | 2 | 1.94 % | 0 | 0.00 % | 5.10 | 0.241-107.521 | p = 0.295 |
All mutations | 8 | 7.77 % | 1 | 0.97 % | 8.59 | 1.054–69.975 | p = 0.046 | |